1044256-84-9

Usage

Uses

Used in Organic Synthesis:
(3-Bromo-2-Methoxyphenyl)Methanamine is used as an intermediate in organic synthesis for the production of various drugs and bioactive molecules. Its unique chemical structure allows for the creation of a wide range of compounds with diverse applications.
Used in Pharmaceutical Research:
In pharmaceutical research, (3-Bromo-2-Methoxyphenyl)Methanamine is utilized as a key component in the development of new drugs and therapeutic agents. Its versatility in chemical reactions enables the synthesis of potential treatments for various diseases and conditions.
Used in Antifungal Applications:
(3-Bromo-2-Methoxyphenyl)Methanamine has been studied for its potential antifungal properties, making it a candidate for use in the development of antifungal agents to combat fungal infections.
Used in Antibacterial Applications:
Similarly, (3-broMo-2-Methoxyphenyl)MethanaMine has also been investigated for its potential antibacterial properties, indicating its possible use in the creation of antibacterial drugs to treat bacterial infections.

Upstream product

• 1044256-82-7 1-azidomethyl-3-bromo-2-methoxy-benzene 
• 1177558-48-3 2-{[3-bromo-2-(methyloxy)phenyl]methyl}-1H-isoindole-1,3(2H)-dione 

Downstream Products

• 1177558-69-8 1,1-dimethylethyl {[3-bromo-2-(methyloxy)phenyl]methyl}carbamate 

Relevant academic research and scientific papers

METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS

Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an α-adrenergic modulator. The compounds and methods are also use

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention is directed to novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use as dual chromaphores having inhibitory activity against PDE4 and muscarinic acetylcholine receptors (mAChRs), and thus being useful for treating respiratory diseases.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention relates to novel compounds of Formula (I) and their use in the treatment of respiratory diseases, including anti-inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.